CU-CPT-8m is primarily utilized in the field of cancer research due to its potential as an anticancer agent. It is studied for its ability to inhibit the growth of tumor cells by targeting specific cellular pathways involved in cancer progression. Researchers are exploring its efficacy in inducing apoptosis, or programmed cell death, in various cancer cell lines. Additionally, CU-CPT-8m is being investigated for its role in enhancing the effectiveness of existing chemotherapy drugs, potentially reducing the required dosage and minimizing side effects. Its application extends to preclinical studies where it is used to understand the mechanisms of drug resistance and to develop novel therapeutic strategies.